|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAD17 |
Gene summary for RAD17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAD17 | Gene ID | 5884 |
| Gene name | RAD17 checkpoint clamp loader component | |
| Gene Alias | CCYC | |
| Cytomap | 5q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | O75943 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5884 | RAD17 | LZE4T | Human | Esophagus | ESCC | 2.71e-04 | 1.19e-01 | 0.0811 |
| 5884 | RAD17 | LZE8T | Human | Esophagus | ESCC | 2.06e-04 | 6.80e-02 | 0.067 |
| 5884 | RAD17 | LZE20T | Human | Esophagus | ESCC | 9.20e-03 | 4.29e-02 | 0.0662 |
| 5884 | RAD17 | LZE24T | Human | Esophagus | ESCC | 8.19e-10 | 2.32e-01 | 0.0596 |
| 5884 | RAD17 | LZE21T | Human | Esophagus | ESCC | 1.21e-03 | 1.29e-01 | 0.0655 |
| 5884 | RAD17 | P1T-E | Human | Esophagus | ESCC | 1.93e-05 | 1.69e-01 | 0.0875 |
| 5884 | RAD17 | P2T-E | Human | Esophagus | ESCC | 8.76e-28 | 4.28e-01 | 0.1177 |
| 5884 | RAD17 | P4T-E | Human | Esophagus | ESCC | 4.56e-20 | 2.69e-01 | 0.1323 |
| 5884 | RAD17 | P5T-E | Human | Esophagus | ESCC | 1.77e-05 | 3.35e-02 | 0.1327 |
| 5884 | RAD17 | P8T-E | Human | Esophagus | ESCC | 2.91e-04 | 1.02e-01 | 0.0889 |
| 5884 | RAD17 | P9T-E | Human | Esophagus | ESCC | 8.53e-17 | 1.09e-01 | 0.1131 |
| 5884 | RAD17 | P10T-E | Human | Esophagus | ESCC | 1.01e-08 | 1.20e-01 | 0.116 |
| 5884 | RAD17 | P11T-E | Human | Esophagus | ESCC | 1.95e-08 | 3.62e-01 | 0.1426 |
| 5884 | RAD17 | P12T-E | Human | Esophagus | ESCC | 1.50e-12 | 2.69e-01 | 0.1122 |
| 5884 | RAD17 | P15T-E | Human | Esophagus | ESCC | 7.07e-14 | 1.61e-01 | 0.1149 |
| 5884 | RAD17 | P16T-E | Human | Esophagus | ESCC | 3.40e-19 | 2.61e-01 | 0.1153 |
| 5884 | RAD17 | P17T-E | Human | Esophagus | ESCC | 4.43e-03 | 2.16e-01 | 0.1278 |
| 5884 | RAD17 | P20T-E | Human | Esophagus | ESCC | 1.78e-18 | 2.43e-01 | 0.1124 |
| 5884 | RAD17 | P21T-E | Human | Esophagus | ESCC | 5.14e-09 | 1.58e-01 | 0.1617 |
| 5884 | RAD17 | P22T-E | Human | Esophagus | ESCC | 9.60e-09 | 1.45e-01 | 0.1236 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
| GO:00000775 | Esophagus | ESCC | DNA damage checkpoint | 78/8552 | 115/18723 | 1.27e-06 | 1.56e-05 | 78 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
| GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
| GO:190199113 | Esophagus | ESCC | negative regulation of mitotic cell cycle phase transition | 112/8552 | 179/18723 | 3.69e-06 | 4.03e-05 | 112 |
| GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
| GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAD17 | SNV | Missense_Mutation | novel | c.331N>A | p.Glu111Lys | p.E111K | O75943 | protein_coding | deleterious(0) | possibly_damaging(0.683) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| RAD17 | SNV | Missense_Mutation | c.937A>G | p.Lys313Glu | p.K313E | O75943 | protein_coding | tolerated(0.08) | benign(0.015) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RAD17 | SNV | Missense_Mutation | c.217N>C | p.Glu73Gln | p.E73Q | O75943 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RAD17 | SNV | Missense_Mutation | c.1496C>T | p.Thr499Met | p.T499M | O75943 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RAD17 | SNV | Missense_Mutation | novel | c.259G>A | p.Glu87Lys | p.E87K | O75943 | protein_coding | deleterious(0.02) | benign(0.105) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAD17 | insertion | In_Frame_Ins | novel | c.832_833insCGCGATCTCAGCTCATTGCAAGCTCTGCCTCCCAGGTTC | p.Glu278delinsAlaArgSerGlnLeuIleAlaSerSerAlaSerGlnValGln | p.E278delinsARSQLIASSASQVQ | O75943 | protein_coding | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| RAD17 | SNV | Missense_Mutation | rs150902866 | c.608C>T | p.Ala203Val | p.A203V | O75943 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RAD17 | SNV | Missense_Mutation | novel | c.1591N>G | p.Leu531Val | p.L531V | O75943 | protein_coding | tolerated(0.09) | benign(0.04) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RAD17 | SNV | Missense_Mutation | c.637N>A | p.Gly213Arg | p.G213R | O75943 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RAD17 | SNV | Missense_Mutation | novel | c.1846N>A | p.Glu616Lys | p.E616K | O75943 | protein_coding | tolerated(0.07) | benign(0.039) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |